Searched for
CHIMERIC ANTIGEN RECEPTOR
Eli Lilly bets on next-generation cell therapy with $2.4 billion deal for OrnaEli Lilly will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients' own cells to gen...- Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of opsImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ...
- Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatmentThis therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and significantly r...
- Bengaluru company launches low-cost treatment for blood cancerImmuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Ho...
- Ajay Hinduja on advancing cancer care: Insights on CAR-T therapy innovationIndia has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja Hospital, led by Dr. ...
- How is India transforming the global biopharma landscape?In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...
- Small-cap investing: Combination of hard work & patience. 5 stocks from different sectors with an upside potential of up to 26%A key market attribute is the ability to assess the probability of a future event – and adjusting expectations accordingly. For, expectatio...
- India eases drug approval process, waives local trials for advanced therapiesIn a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major intern...
- CDSCO approves India's first CAR-T cell therapy against certain blood cancersIndian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for ...
- Blackstone sets its sights on buying out Hamieds from CiplaNon-binding bid likely next week for 33.4% stake, will trigger open offer for 26% more. At current mkt value deal size could be over $6 bn ...
- Laurus Labs shares rise over 4% as co acquires additional stake in lmmunoACTLaurus Labs is set to increase its stake in Immunoadoptive Cell Therapy (lmmunoACT) by 7.24% for $10.6m, taking its total stake in the comp...
- Seeking technology, manufacturing partnership with Indian pharma companies, says Mexico foreign secretaryThe Mexican government has partnered with ImmunoAct, an IIT Bombay-incubated company which is developing cutting-edge chimeric antigen rece...
- Immuneel's CAR-T cell therapy reports positive in early phase-2 trials in IndiaThe early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and child...
- Centre of Excellence for cancer care and blood disorders at Amrita Hospital, FaridabadAmrita Hospital's Department of Hematology, Medical Oncology and BMT helps patients treat blood disorders, benign diseases, as well as bloo...
- Immuneel Therapeutics raises $15 million in fundingImmuneel Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular im...
- Cellogen to bring next-gen cancer therapy to India"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...
- Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy companyAs per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...
- Indegene acquires US-based Medical Marketing Economics for $10 millionIndegene raised $200 million from investment firms Carlyle and Brighton Park Capital in February and is looking at more acquisitions in the...
- Immuneel signs pact with Hospital Clínic de Barcelona to work on cancer therapyThe collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press ...
- Glenmark rises armed with research after five year hiatusIt may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.
Load More
